Beta Pharma lands cancer drug manufacturing and development contract
Adva-27a is an anti-cancer compound which has demonstrated the ability to kill resistant breast cancer cells (MCF-7/MDR) and small-cell lung cancer cells (H69AR) in preclinical studies conducted to date.
Montreal-based Beta Pharma Canada - an affiliate of Beta Pharma with offices and facilities in Connecticut (USA) and Shanghai (China) – will also provide synthesis parameters for future scale-up and large scale manufacturing of the drug.
Sunshine CEO Steve Slilaty said: “We are delighted to be working with Beta Pharma Canada with excellent in-house synthesis capability and can amass additional resources through its corporate affiliations” adding that “We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month.”
